异常凝血酶原作为接受立体定向体部放疗的局限性肝细胞癌患者预后的替代标志物。
PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy.
作者信息
Cho Ick Joon, Jeong Jae-Uk, Nam Taek-Keun, Joo Young-Eun, Cho Sung-Bum, Kim Yong-Hyub, Song Ju-Young, Yoon Mee Sun, Ahn Sung-Ja, Chung Woong-Ki
机构信息
Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
出版信息
Radiat Oncol J. 2022 Mar;40(1):20-28. doi: 10.3857/roj.2021.00934. Epub 2022 Mar 25.
PURPOSE
This study aimed to determine the correlation between protein induced by vitamin K absence or antagonist-II (PIVKA-II) and stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma (HCC).
MATERIALS AND METHODS
Sixty-one patients received SBRT between 2015 and 2020 with a median dose of 48 Gy (range, 39 to 60 Gy) with a median of 4 fractions. Changes in tumor markers before and after SBRT were analyzed.
RESULTS
The median follow-up period was 31 months (range, 12 to 64 months). The estimated 2-year in-field failure-free survival, progression-free survival (PFS), and overall survival rates were 82.0%, 39.3%, and 96.7%, respectively. Patients with decreased PIVKA-II levels through SBRT had significantly few in-field failures (p = 0.005). Patients with PIVKA-II levels of ≤25 mAU/mL after SBRT had significantly long PFS (p = 0.004).
CONCLUSION
PIVKA-II could be a useful surrogate marker for response or survival outcomes in patients with localized HCC receiving SBRT.
目的
本研究旨在确定维生素K缺乏或拮抗剂-II诱导蛋白（PIVKA-II）与肝细胞癌（HCC）患者立体定向体部放疗（SBRT）之间的相关性。
材料与方法
2015年至2020年期间，61例患者接受了SBRT，中位剂量为48 Gy（范围39至60 Gy），中位分割次数为4次。分析了SBRT前后肿瘤标志物的变化。
结果
中位随访期为31个月（范围12至64个月）。估计的2年野内无失败生存率、无进展生存率（PFS）和总生存率分别为82.0%、39.3%和96.7%。通过SBRT使PIVKA-II水平降低的患者野内失败显著较少（p = 0.005）。SBRT后PIVKA-II水平≤25 mAU/mL的患者PFS显著较长（p = 0.004）。
结论
PIVKA-II可能是接受SBRT的局限性HCC患者反应或生存结果的有用替代标志物。
Zotero 插件